Altimmune Inc. (ALT) has a clinical trial catalyst to watch in the coming weeks, which has the potential to impact its stock performance.
The company is expected to release 48-week data from its Phase 2b IMPACT trial of Pemvidutide in metabolic dysfunction association steatohepatitis (MASH) before the end of this year.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com